A double-blind, randomized, comparative study of Cabaser [cabergoline] and Sinemet CR [controlled-release levodopa/carbidopa] for the treatment of nocturnal disability in levodopa-treated Parkinson's disease patients

Trial Profile

A double-blind, randomized, comparative study of Cabaser [cabergoline] and Sinemet CR [controlled-release levodopa/carbidopa] for the treatment of nocturnal disability in levodopa-treated Parkinson's disease patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2005

At a glance

  • Drugs Cabergoline; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top